Quick Answer
Grace Therapeutics, Inc. reported Cash and Equivalents of $22.13 million for fiscal year 2025.
Grace Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $22.13M | -3.8% |
| 2024 | $23.00M | -17.5% |
| 2023 | $27.88M | -8.1% |
| 2022 | $30.34M | -40.4% |
| 2021 | $50.94M | +257.7% |
| 2020 | $14.24M | -15.6% |
| 2019 | $16.87M | +0.0% |
| 2019 | $16.87M | +162.7% |
| 2018 | $6.42M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $18.67M | +68.9% | +10.7% |
| September 30, 2025 | $16.86M | +11.3% | -15.7% |
| June 30, 2025 | $20.00M | +3.2% | -9.6% |
| March 31, 2025 | $22.13M | -3.8% | +100.2% |
| December 31, 2024 | $11.05M | -40.4% | -27.1% |
| September 30, 2024 | $15.15M | -43.9% | -21.9% |
| June 30, 2024 | $19.39M | -10.3% | -15.7% |
| March 31, 2024 | $23.00M | -17.5% | +24.0% |
- Grace Therapeutics, Inc. showed a decrease of -3.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Grace Therapeutics, Inc.’s cash and equivalents has grown by 244.6% (from $6.42 million to $22.13 million).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: